Cited by 228Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.

Open access

Reaven, Peter D., Emanuele, Nicholas V., Wiitala, Wyndy L., Bahn, Gideon D., Reda, Domenic J., McCarren, Madeline, Duckworth, William C., Hayward, Rodney A.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1806802PMC PMC6706253

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: We previously reported that a median of 5.6 years of intensive as compared with standard glucose lowering in 1791 military veterans with type 2 diabetes resulted in a risk of major cardiovascular events that was significantly lower (by 17%) after a total of 10 years of combined intervention and observational follow-up. We now report the full 15-year follow-up. METHODS: We observationally followed enrolled participants (complete cohort) after the conclusion of the original clinical trial by using central databases to identify cardiovascular events, hospitalizations, and deaths. Participants were asked whether they would be willing to provide additional data by means of surveys and chart reviews (survey cohort). The prespecified primary outcome was a composite of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, and death from cardiovascular causes. Death from any cause was a prespecified secondary outcome. RESULTS: There were 1655 participants in the complete cohort and 1391 in the survey cohort. During the trial (which originally enrolled 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy group (892 participants) and the standard-therapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a period of 15 years of follow-up (active treatment plus post-trial observation), the risks of major cardiovascular events or death were not lower in the intensive-therapy group than in the standard-therapy group (hazard ratio for primary outcome, 0.91; 95% confidence interval [CI], 0.78 to 1.06; P = 0.23; hazard ratio for death, 1.02; 95% CI, 0.88 to 1.18). The risk of major cardiovascular disease outcomes was reduced, however, during an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI, 0.70 to 0.99), but this benefit did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI, 0.90 to 1.75). CONCLUSIONS: Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated. There was no evidence of a legacy effect or a mortality benefit with intensive glucose control. (Funded by the VA Cooperative Studies Program; VADT ClinicalTrials.gov number, NCT00032487.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1806802

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138

Flagged first, then by citations

Show all 36 references

Sorted by citations

Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 799
2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O. C., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 443
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage
Diener, H., & Hankey, G. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.072 · Cited by 394
Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis
Edgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart-Ayala, H., Bailey, J., Corbin, A., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046464 · Cited by 352
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 235
Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management
Zotin, M. C. Z., Sveikata, L., Viswanathan, A., & Yilmaz, P. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000913 · Cited by 221
Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study
Zhang, Y., Cui, Y., Shen, M., Zhang, J., Liu, B., Dai, M., Chen, L., Han, D., Fan, Y., Zeng, Y., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108227 · Cited by 184
Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study
Goldberg, R. B., Orchard, T. J., Crandall, J. P., Boyko, E. J., Budoff, M. J., Dabelea, D., Gadde, K. M., Knowler, W. C., Lee, C. G., Nathan, D. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056756 · Cited by 191
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Primary prevention of ischaemic heart disease: populations, individuals, and health professionals
Gupta, R., & Wood, D. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31893-8 · Cited by 159
Cardiovascular outcomes in type 1 and type 2 diabetes
Rosengren, A., & Dikaiou, P. (2023) · Diabetologia · doi:10.1007/s00125-022-05857-5 · Cited by 162
Diagnosis and Treatment of Type 2 Diabetes in Adults
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 145
A PEDOT:PSS conductive hydrogel incorporated with Prussian blue nanoparticles for wearable and noninvasive monitoring of glucose
Xu, C., Jiang, D., Ge, Y., Huang, L., Xiao, Y., Ren, X., Liu, X., Zhang, Q., & Wang, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.134109 · Cited by 145
Glycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 149
Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
Lind, M., Imberg, H., Coleman, R. L., Nerman, O., & Holman, R. R. (2021) · Diabetes Care · doi:10.2337/dc20-2439 · Cited by 128
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Fuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0977-z · Cited by 125
Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 119
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis
Edgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart‐Ayala, H., Bailey, J. D., Corbin, A., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.1161/circulationaha.120.04646 · Cited by 113
GLP-1 Receptor Agonists
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 126
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 93
Biguanides: Species with versatile therapeutic applications
Kathuria, D., Raul, A. D., Wanjari, P. J., & Bharatam, P. V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113378 · Cited by 87
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 91
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus
Chen, Y., Zhao, X., & Wu, H. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312192 · Cited by 73
Type 2 Diabetes
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 72
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure
Schernthaner, G., Brand, K. M. G., & Bailey, C. J. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155160 · Cited by 72
Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function
Wang, J., Huang, X., Liu, H., Chen, Y., Li, P., Liu, L., Li, J., Ren, Y., Huang, J., Xiong, E., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1122494 · Cited by 67
Rethinking Chronic Kidney Disease in the Aging Population
Alfano, G., Perrone, R., Fontana, F., Ligabue, G., Giovanella, S., Ferrari, A., Gregorini, M., Cappelli, G., Magistroni, R., & Donati, G. (2022) · Life · doi:10.3390/life12111724 · Cited by 72
Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 65
Rate of glycemic control and associated factors among type two diabetes mellitus patients in Ethiopia: a cross sectional study
Nigussie, S., Birhan, N., Amare, F., Mengistu, G., Adem, F., & Abegaz, T. M. (2021) · PLOS ONE · doi:10.1371/journal.pone.0251506 · Cited by 62
“The role of achieving the optimal blood glucose level in preventing the development and progression of complications is an established fact [9].”
Background
Metas no tratamento do diabetes
de Almeida-Pititto, B., Rodrigues, M. L. D., de Moura, F. F., Lamounier, R. N., Vencio, S. A. C., Calliari, L. E., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-3 · Cited by 99
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
Patoulias, D., Papadopoulos, C. E., Stavropoulos, K., Zografou, I., Doumas, M. N., & Karagiannis, A. I. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13831 · Cited by 59
Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
Chen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 67
Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction
Schmitt, V. H., Hobohm, L., Münzel, T. F., Wenzel, P., Gori, T., & Keller, K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.003 · Cited by 59
MiR‐144 protects the heart from hyperglycemia‐induced injury by regulating mitochondrial biogenesis and cardiomyocyte apoptosis
Tao, L., Huang, X., Xu, M., Yang, L., & Hua, F. (2019) · The FASEB Journal · doi:10.1096/fj.201901838r · Cited by 53
Genetic-code-expanded cell-based therapy for treating diabetes in mice
Chen, C., Yu, G., Huang, Y., Cheng, W., Li, Y., Sun, Y. X., Ye, H., & Liu, T. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00899-z · Cited by 51
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 60
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
Dabravolski, S. A., Zhuravlev, A. D., Kartuesov, A. G., Borisov, E. E., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105371 · Cited by 50
Predicting 5- and 10-year mortality risk in older adults with diabetes
Griffith, K. N., Prentice, J. C., Mohr, D. C., & Conlin, P. R. (2020) · Diabetes Care · doi:10.2337/dc19-1870 · Cited by 48
Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells
Arroyave, F., Montaño, D., & Lizcano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228685 · Cited by 52
The legacy effect in diabetes: are there long-term benefits?
Folz, R., & Laiteerapong, N. (2021) · Diabetologia · doi:10.1007/s00125-021-05539-8 · Cited by 46
A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 46
Type 2 Diabetes
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 50
Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes
Carew, A. S., Levy, A. P., Ginsberg, H. N., Coca, S. G., Lache, O., Ransom, T. P. P., Byington, R. P., Rimm, E. B., Sapp, J. L., Gardner, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.051 · Cited by 44
Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia
Regassa, L. D., Tola, A., & Ayele, Y. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.532719 · Cited by 41
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids
Semova, I., Levenson, A. E., Krawczyk, J., Bullock, K. H., Gearing, M. E., Ling, A. V., Williams, K., Miao, J., Adamson, S. S., Shin, D., et al. (2022) · Circulation · doi:10.1161/circulationaha.120.045373 · Cited by 43
Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 41
Glycemic control and its associated factors in type 2 diabetes patients at Felege Hiwot and Debre Markos Referral Hospitals
Shita, N. G., & Iyasu, A. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13673-5 · Cited by 40
Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms
Izundegui, D. G., & Nayor, M. G. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01449-0 · Cited by 39
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 38
Diabetes and stroke: An important complication
Bloomgarden, Z. T., & CHILTON, R. J. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13142 · Cited by 38
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Tye, S. C., Jongs, N., Coca, S. G., Sundström, J., Arnott, C. G., Neal, B. C., Perkovic, V., Mahaffey, K. W., Vart, P., & Heerspink, H. J. L. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01619-0 · Cited by 34
Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular events
Sheng, L., Yang, G., Chai, X., Zhou, Y., Sun, X., & Xing, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1323571 · Cited by 35
HMGB1 impairs endothelium‐dependent relaxation in diabetes through TLR4/eNOS pathway
Zhu, Z., Peng, X., Li, X., Tu, T., Yang, H., Teng, S., Zhang, W., Xing, Z., Tang, J., Hu, X., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000242r · Cited by 32
The right place for Sulphonylureas today: Part of ‘Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus’
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 34
Prevalence, treatment, control of type 2 diabetes and the risk factors among elderly people in Shenzhen: results from the urban Chinese population
Sun, Y., Ni, W., Yuan, X., Chi, H., & Xu, J. (2020) · BMC Public Health · doi:10.1186/s12889-020-09045-1 · Cited by 29
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus
Sasako, T., Yamauchi, T., & Ueki, K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0325 · Cited by 32
Review of the veteran affairs diabetes trial: Lessons learned
Tran, K., & Reaven, P. D. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09558-5 · Cited by 27
Self-citation
Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor
Nahmias, A., Stahel, P., Xiao, C., & Lewis, G. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00100 · Cited by 29
Glucagon: Its evolving role in the management of hypoglycemia
Isaacs, D. M., Clements, J. N., Turco, N., & Hartman, R. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2534 · Cited by 29
The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy
Tao, L., Wang, T., Lu, Z., Hua, F., & Li, J. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.192 · Cited by 27
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study
Hanssen, N. M. J., Scheijen, J. L. J. M., Houben, A. J. H. M., van de Waarenburg, M. P. H., Berendschot, T. T. J. M., Webers, C. A. B., Reesink, K. D., van Greevenbroek, M. M. J., Kallen, C., Schaper, N. C., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.02.002 · Cited by 26
Leveraging machine learning and big data for optimizing medication prescriptions in complex diseases: a case study in diabetes management
Hosseini, M. M., Zargoush, M., Alemi, F., & Kheirbek, R. (2020) · Journal Of Big Data · doi:10.1186/s40537-020-00302-z · Cited by 27
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Kim, J., & Kwon, H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0377 · Cited by 31
Association of Social and Behavioral Risk Factors With Mortality Among US Veterans With COVID-19
Kelly, J. D., Bravata, D. M., Bent, S., Wray, C. M., Leonard, S. J., Boscardin, W. J., Myers, L. J., & Keyhani, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.13031 · Cited by 25
ERK/RSK-mediated phosphorylation of Y-box binding protein-1 aggravates diabetic cardiomyopathy by suppressing its interaction with deubiquitinase OTUB1
Zhong, X., Wang, T., Zhang, W., Wang, M., Xie, Y., Dai, L., He, X., Madhusudhan, T., Zeng, H., & Wang, H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101989 · Cited by 25
The cardiovascular complications of diabetes: a striking link through protein glycation
Ahmad, M. N., Farah, A. I., & Al‐Qirim, T. M. (2020) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2020-0021 · Cited by 24
Association between the Plasma-Glycosylated Hemoglobin A1c/High-Density Lipoprotein Cholesterol Ratio and Carotid Atherosclerosis: A Retrospective Study
Hu, X., Li, W., Wang, C., Zhang, H., Lu, H., Li, G., Zhou, Y., & Dong, H. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9238566 · Cited by 24
Glycaemic control in people with diabetes following acute myocardial infarction
Esdaile, H., Hill, N. E., Mayet, J., & Oliver, N. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110644 · Cited by 28
SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART
Rosén, H. C., Mohammad, M. A., Jernberg, T., James, S. K., Oldgren, J., & Erlinge, D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101032 · Cited by 25
Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial
Derosa, G., D’Angelo, A., Martinotti, C., Valentino, M. C., Matteo, S. D., Bruno, G. M., & Maffioli, P. (2020) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000673 · Cited by 23
Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 23
Genetics of Type 2 Diabetes: Opportunities for Precision Medicine
Kim, D. S., Gloyn, A. L., & Knowles, J. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.346 · Cited by 25
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 23
Management of Diabetes in Patients Undergoing Bariatric Surgery
Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 24
Remission of Type 2 Diabetes After Treatment With a High-Fiber, Low-Fat, Plant-Predominant Diet Intervention: A Case Series
Gunadhar, P., Goodwin, S. M., Livingston, K. A., & Karlsen, M. C. (2023) · American Journal of Lifestyle Medicine · doi:10.1177/15598276231181574 · Cited by 26
Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population
Schmitt, V. H., Billaudelle, A.-M., Schulz, A., Keller, K., Hahad, O., Tröbs, S., Koeck, T., Michal, M., Schuster, A. K.-G., Toenges, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173851 · Cited by 21
Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT)
Agrawal, L., Azad, N., Bahn, G. D., Reaven, P. D., Hayward, R. A., Reda, D. J., Emanuele, N. V., VADT Study Group, Abraira, C., Duckworth, W. C., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0891 · Cited by 20
Self-citation
Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study
Funamizu, T., Iwata, H., Nishida, Y., Miyosawa, K., Doi, S., Chikata, Y., Shitara, J., Endo, H., Wada, H., Naito, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00996-8 · Cited by 23
Role of Yoga and Its Plausible Mechanism in the Mitigation of DNA Damage in Type-2 Diabetes: A Randomized Clinical Trial
Nair, R. G., Vasudev, M. M., & Mavathur, R. N. (2021) · Annals of Behavioral Medicine · doi:10.1093/abm/kaab043 · Cited by 19
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Impact of Diabetes Control on Subclinical Atherosclerosis: Analysis from Coronary Computed Tomographic Angiography Registry
Park, G., Lee, C. H., Lee, S., Yun, S., Kim, Y., Kim, Y., Won, K.-B., Ann, S. H., Kim, S.-J., Kang, J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0073 · Cited by 18
The Legacy Effect in the Prevention of Cardiovascular Disease
Esmel, E. V., Naval-Álvarez, J., & Sacanella, E. (2020) · Nutrients · doi:10.3390/nu12113227 · Cited by 17
Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes
Kloecker, D. E., Khunti, K., Davies, M. J., Pitocco, D., & Zaccardi, F. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.047 · Cited by 16
Accelerated brain aging in individuals with diabetes: Association with poor glycemic control and increased all-cause mortality
Jha, M. K., Fatt, C. C., Minhajuddin, A., Mayes, T. L., Berry, J. D., & Trivedi, M. H. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105921 · Cited by 18
Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management
Foussard, N., Dari, L., Ducasse, É., Rigalleau, V., Mohammedi, K., & Caradu, C. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104164 · Cited by 20
Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials
Kuzemczak, M., Ibrahem, A., & Alkhalil, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01056-z · Cited by 16
Risk Factors and Dynamic Nomogram Development for Surgical Site Infection Following Open Wedge High Tibial Osteotomy for Varus Knee Osteoarthritis: A Retrospective Cohort Study
Guo, H., Song, B., Zhou, R., Yu, J., Chen, P., Yang, B., Pan, N., Li, C., Zhu, Y., & Wang, J. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s436816 · Cited by 14
Dihydromyricetin ameliorates diabetic renal fibrosis via regulating SphK1 to suppress the activation of NF-κB pathway
Wen, M., Sun, X., Pan, L., Jing, S., Zhang, X., Liang, L., Xiao, H., Liu, P., Xu, Z., Zhang, Q., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176799 · Cited by 14
Effectiveness and safety of sodium–glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
Sriphrapradang, C., Thewjitcharoen, Y., Buranapin, S., Sawanyawisuth, K., Yenseung, N., Ubonchareon, W., Limpijankit, L., & Himathongkam, T. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1808454 · Cited by 14
Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study
Hayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 14
Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: Can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort
Cardoso, C. R. L., Leite, N. C., & Salles, G. F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108124 · Cited by 13
Association of Cardiovascular Health Score With Early‐ and Later‐Onset Diabetes and With Subsequent Vascular Complications of Diabetes
Choi, Y., Jacobs, D. R., Bancks, M. P., Lewis, C. E., Cha, E., Yan, F., Carnethon, M. R., Schreiner, P. J., & Duprez, D. A. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027558 · Cited by 12
Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study
Hata, S., Ushigome, E., Hosomi, Y., Yoshimura, T., Takegami, M., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-022-01136-3 · Cited by 13
Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation
Senior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12

Authors: Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A.
Affiliations: VA Ann Arbor Healthcare System (US)
Edward Hines, Jr. VA Hospital (US)
ORCID: Reaven, Peter D.
Wiitala, Wyndy L.
Reda, Domenic J.
Hayward, Rodney A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-06-06
Volume: 380
Issue: 23
Pages: 2215-2224
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1806802
PMC: PMC6706253
OpenAlex: W2955148946
Cited by: 228
References: 36
Citations by year: 2026: 12 · 2025: 13 · 2024: 21 · 2023: 35 · 2022: 35 · 2021: 34 · 2020: 50 · 2019: 27
FWCI: 29.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: VA Cooperative Studies Program (NCT00032487)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: tight glycemic control, type 2 diabetes, HbA1c, cardiovascular events, major adverse cardiovascular events, long-term follow-up, military veterans, glycemic control, cardiovascular mortality, myocardial infarction, stroke, congestive heart failure, amputation
MeSH terms: Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Quality of Life, Veterans, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks